The role of botulinus toxin type A in treatment – with special reference to children

Gordon, Neil

doi:10.1016/s0387-7604(98)00099-0

Cited by 21 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drugs (Pranzatelli 1996), surgery (De Salles 1996, or botulinum toxin injections (Gordon 1999) do not offer help. Once the diagnosis of a dyskinetic eye movement disorder is made, appropriate parental and educational management techniques should be introduced.…”

Section: Discussionmentioning

confidence: 99%

Visual impairment due to a dyskinetic eye movement disorder in children with dyskinetic cerebral palsy

Jan¹,

Lyons²,

Heaven³

et al. 2001

Dev Med Child Neurol

View full text Add to dashboard Cite

Neurological lesions that cause dyskinetic cerebral palsy (CP) commonly involve ocular movements. This report describes a group of 14 children (nine males, five females) whose CP is associated with severe dyskinetic eye movements. Ages ranged from 4 months to 13 years (mean 6.9 years). Clinical features of this eye movement disorder are discussed and defined. The visual function of these children is slow, variable, and highly inefficient. They are often misdiagnosed as blind, due to cortical visual impairment. Early recognition of dyskinetic eye moment disorder and appropriate developmental and educational management are important.

show abstract

Section: Discussionmentioning

confidence: 99%

Visual impairment due to a dyskinetic eye movement disorder in children with dyskinetic cerebral palsy

Jan¹,

Lyons²,

Heaven³

et al. 2001

Dev Med Child Neurol

View full text Add to dashboard Cite

show abstract

“…Hyperhidrosis causes a significant impact and stress in the patient’s life, with limitations in work, school, and physical activities and emotional problems (3,6). Specific therapies used to reduce sweat production include antiperspirants, tap water iontophoresis, botulinum toxin type A, anticholinergic drugs, and sympathectomy (1,6–16).…”

Section: Introductionmentioning

confidence: 99%

Palmar Hyperhidrosis: Long‐term Follow‐up of Nine Children and Adolescents Treated with Botulinum Toxin Type A

Santos

Gomes

Giraldi

et al. 2009

Pediatric Dermatology

View full text Add to dashboard Cite

Primary palmar hyperhidrosis in children and adolescents may be severe enough to affect school and physical activities, causing emotional problems, stress in the patient's life, and a compromised quality of life. Nine patients with palmar hyperhidrosis underwent treatment with botulinum A. Before the session, and in the 1-, 3-, 6-, 9-, and 12-month post-session follow-ups, the patients were administered the Minor test, gravimetry, the Scales of Frequency and Severity, and the Questionnaire of Quality of Life. The mean age was 11 years, with seven girls and two boys. Each patient was administered at least one treatment of botulinum toxin in the palm of the hands (75-150 U for palm), with the mean number of sessions 2.2 (range: 1-4). All sessions in the patients resulted in drying of the hands, with a mean duration of effect of 7 months. Botulinum toxin A controls excessive sweat in the palms of children and adolescents who have primary palmar hyperhidrosis, with an improvement in the quality of life. The therapy is safe and effective in this pediatric group and can be considered before surgical interventions.

show abstract

“…BTXA has been approved for the treatment of strabismus and blepharospasm in patients age 13 years and older and for cervical dystonia in children age 17 years and older. Its use in children has been extended in a variety of conditions, such as spasticity, hemiplegia, involuntary movements, dystonia, muscle spasm, spasmodic torticollis, and hemifacial spasm .…”

Section: Discussionmentioning

confidence: 99%

Quality of Life and Social Isolation in Greek Adolescents with Primary Focal Hyperhidrosis Treated with Botulinum Toxin Type A: A Case Series

Kouris

Armyra

Stefanaki

et al. 2014

Pediatric Dermatology

View full text Add to dashboard Cite

Primary hyperhidrosis, although extensively documented in adults, typically has onset that dates back to early childhood. It is an unpleasant and socially disabling problem for the affected child, but little attention has been paid to the disease in adolescents. The objective of the current study was to evaluate the effectiveness of botulinum toxin type A (BTXA) in adolescents with primary palmar and axillary hyperhidrosis and to determine its effect on quality of life and social isolation. Thirty-five individuals (17 girls, 18 boys) with moderate to severe palmar and axillary hyperhidrosis were treated with BTXA (onabotulinum). Patients were examined at baseline and 6 months after treatment. The Hyperhidrosis Disease Severity Scale (HDSS) was used to evaluate disease severity and the Children's Dermatology Life Quality Index (CDLQI) was used to assess quality of life. The University of California at Los Angeles loneliness scale (UCLA version 3) was used to assess personal perception of loneliness and social isolation. The median age of the participants was 14 years, and 48.6% were female. Twenty-one had palmar hyperhidrosis, and 14 had axillary hyperhidrosis. Total CDLQI and social isolation scores decreased significantly after treatment with BTXA (both p < 0.001). There was a significant difference between pre- and post-treatment levels of severity of hyperhidrosis. No statistically significant difference was documented for CDLQI and UCLA scores between boys and girls. Treatment of hyperhidrosis with BTXA resulted in improvement in quality of life, social skills, and activities.

show abstract

The role of botulinus toxin type A in treatment – with special reference to children

Cited by 21 publications

References 25 publications

Visual impairment due to a dyskinetic eye movement disorder in children with dyskinetic cerebral palsy

Visual impairment due to a dyskinetic eye movement disorder in children with dyskinetic cerebral palsy

Palmar Hyperhidrosis: Long‐term Follow‐up of Nine Children and Adolescents Treated with Botulinum Toxin Type A

Quality of Life and Social Isolation in Greek Adolescents with Primary Focal Hyperhidrosis Treated with Botulinum Toxin Type A: A Case Series

Contact Info

Product

Resources

About